State-of-the-Art Review : Secondary Prevention of Myocardial Infarction: Beneficial Effect of Combining Oral Anticoagulant Plus Aspirin

DeWood MA , Spores J. , Notske R. , et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897.

Mizuno K. , Miyamoto A. , Satomura K. , et al. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet 1991;337:809.

Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999;340:115.

Libby P. , Mach F. , Schönbeck U. , et al. Regulation of the thrombotic potential of atheroma. Thromb Haemost 1999;82:736.

Mann JM , Kaski JC , Pereira WI , et al. Histological patterns of atherosclerotic plaques in unstable angina patients vary according to clinical presentation. Heart 1998;80:19.

Farb A. , Burke AP , Tang AL , et al. Coronary plaque erosion without rupture into a lipid core. Circulation 1996;93:1354.

Flugelman MY , Virmani R. , Correa R. , et al. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from stable to the unstable clinical state. Circulation 1993;88:2493.

Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844.

Mann J. , Davies MJ Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999;82: 265.

Cimminiello C. , Toschi V. Atherothrombosis: the role of platelets . Eur Heart J 1999;1(suppl A):A8.

Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126.

Moreno PR , Bernardi VH , Lopez-Cuellar J. , et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation 1996;94:3090.

Badimon JJ , Lettino M. , Toschi V. , et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999;99:1780.

Mailhac A. , Badimon JJ , Fallon JT , et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(o-gen) and platelets. Circulation 1994;90:988.

Fuster V. , Fallon JT , Badimon JJ , et al. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Thromb Haemost 1997 ;78:247.

Badimon L. , Badimon JJ Mechanism of arterial thrombosis in nonparallel streamlines: platelet thrombi grow at the apex of stenotic severely injured vessel wall. Experimental studies in the pig model. J Clin Invest 1989 ;84:1134.

Gurfinkel E. , Altman R. , Scazziota A. , et al. Importance of thrombosis and thrombolysis in silent ischemia: comparison of patients with acute myocardial infarction and unstable angina. Br Heart J 1994;71:151.

Gimbrone MA Jr.Endothelial disfunction, hemodynamic forces, and atherosclerosis. Thromb Haemost 1999;82:722.

Santos MT , Valles J. , Marcus AJ , et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 1991;87:571.

Tracy PB , Allen DH , Worfolk LA , et al. Monocyte/macrophage regulation of coagulant events. Haemostasis 1996;26(Suppl 1 ):6.

Crovello CS , Furie BC , Furie B. Histidine phosphorylation of P-selectin upon ligand-induced stimulation of human platelets: a novel pathway for cell activation dependent signal transduction. Cell 1995:82:279.

Furie B. , Furie BC Leukocyte crosstalk at the vascular wall. Thromb Haemost 1997;78:306.

Galbusera M. , Zoja C. , Donaldelli R. , et al. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium . Blood 1997;90:1558.

Prentice Crm. Platelets and atherosclerosis. Eur Heart J 1999;1 (suppl A):3.

Kuijper PH , Gallardo Torres HI , Lammers JW , et al. Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood 1997;89:166.

Sinapius D. Morphology of occlusive coronary thrombi. Localization, length, composition, growth. Dtsch Med Wochrenschr 1972; 97:544.

Van Belle E. , Lablanche JM , Bauters C. , et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Natural history and the effect of thrombolysis. Circulation 1998;97:28.

Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287.

Gibbons RJ , Chatterjee K. , Daley J. , et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. Circulation 1999; 99:2829.

Wood D. , Durrington P. , Poulter N. , et al. on Behalf of the Societies. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2): 1.

Cains JA , Théroux P. , Lewis HD , et al. Antithrombotic agents in coronary artery disease. Chest 1998;114(suppl):611.

Willard JE , Lange RA , Hillis LD The use of aspirin in ischemic heart disease. N Engl J Med 1992;97:28.

Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in person recovered from myocardial infarction. JAMA 1980 ;243:661.

Prentice Crm. Antithrombotic therapy in the secondary prevention of myocardial infarction. Am J Cardiol 1993 ;72:175.

Anti-platelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy . Br Med J 1988; 296:320.

ISIS-2 Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. ISIS-2. Lancet 1988;2:349.

Goldstein RE , Andrews M. , Hall J. , et al., for the Multicenter Myocardial Research Group. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996;28:326.

Tajer C. , Hirschson Prado A. , Castagnino J. , et al. Fracaso antiinflamatorio, antitrombotico o sesgo clinico? Aspirina previa y evolucion en la angina inestable: estudio fisiopatologico. Rev Argent Cardiol 1999;67:137.

The Medical Research Council's General Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and increased risk. Lancet 1998 ;351: 233.

Falk E. , Fuster V. Angina pectoris and disease progression. Circulation 1995;92:2033.

Hennekens CH , Dyken ML , Fuster V. Aspirin as a therapeutic agent in cardiovascular association. Circulation 1997;96:2751.

Altman R. , Rouvier J. , Gurfinkel E. , et al. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation 1996;94: 2113.

Hoogendijk Emg , Ten Cate JW. Aspirin and platelets. Lancet 1980;2:93.

Patrignani P. , Filabozzi P. , Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366.

Jakubowski JA , Stampfer MJ , Vaillancourt R. , et al. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985;60:635.

The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345.

The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325: 1261.

Patrono C. Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? Thromb Res 1998 ; 92(suppl 1):7.

Chalmers TC , Matte RJ , Smith J. Jr, et al. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091.

The Sixty Plus Re-infarction Study Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction . Lancet 1980;2:989.

Smith P. , Arnesen H. , Home I. The effect of warfarin on mortality and re-infarction after myocardial infarction . N Engl J Med 1990; 323:147.

Anticoagulants in the secondary prevention of events in coronary thrombosis (ASPECT) research group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction . Lancet 1994;343:499.

Azar AJ , Cannergieter SC , Deckers JW , et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996,27:1349.

Koefoed BG , Federsen C. , Gullov AL , Petersen P. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation . Thromb Haemost 1997;77:845.

van Bergen PF , Jonker JJ , van Hout BA , et al. ASPECT Coordinating Center, Rotterdam, The Netherlands. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 1995;273:925.

Cowburn P. , Cleland Jgf. SPAF-III results. Eur Heart J 1996 ;17: 1129.

Altman R. , Rouvier J. , Gurfinkel E. Oral anticoagulant treatment with and without aspirin. Thromb Haemost 1995;74:506.

Breddin K. , Loew D. , Lechner K. , et al. Secondary prevention of myocardial infarction: a comparison between acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980;9:325.

The EPSIM research group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701.

Julia DG , Chamberlain DA , Pocock SJ A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicenter unblinded randomised clinical trial. Br Med J 1996;313:1429.

Coumadin Aspirin Re-infarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389.

Meade TW , Mellows S. , Brozovic M. , et al. Hemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533.

Raskob GE , Durica SS , Morrissey JH , et al. Effect of treatment with low-dose warfarin-aspirin on activated factor XII. Blood 1995;85:3034.

Champ (Combination Hemotherapy And Mortality Prevention Study). Presented at the 72nd Scientific Sessions of the American Heart Association, Atlanta, Georgia, November 7-10, 1999.

Altman R. , Rouvier J. Oral anticoagulants in patients with mechanical cardiac valves replacement. The role of aspirin [Letter]. Circulation 1997;96.

Cohen M. , Adams PC , Parry G. , et al. and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users . Circulation 1994;89:81.

Williams Mja , Morison MI , Parker JH , et al. Progression of the culprit lesion in unstable coronary disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997;30:364.

Anand SS , Yusuf S. , Pogue J. , et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998;98: 1064.

Hurlen M. , Erikssen J. , Smith P. , et al. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients. J Intern Med 1994;236:299.

Meschengieser SS , Fondevila CG , Frontroth J. , et al. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves . J Thorac Cardiovasc Surg 1997; 113:910.

Anand SS , Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis . JAMA 1999;282:2058.

Miller DB Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies. Arch Intern Med 1997;157:2045.

van Es RF , Grobbee DE , Deckers JW , et al. Antithrombotic treatment following acute ischemic heart disease: acetylsalicylic acid and (or) oral anticoagulants? ASPECT-II, a new study . Ned Tijdschr Geneeskd 1997;141:2129.